Drug or technology

MK-2214

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 3, 2026 · PHASE 1 TRIAL

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

ClinicalTrials.gov

This is a Phase 1 safety and pharmacokinetic study with no reported results; registry records of active or completed trials without posted outcomes represent early-stage work and cannot support efficacy or clinical claims.

PreliminaryNCT05466422 Alzheimer Disease Merck Sharp & Dohme

Reported

Sample size34

PhasePhase 1

Primary outcome: Adverse events m…Up to approximately 297 days

AUG 14, 2026 · PHASE 2 TRIAL

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

ClinicalTrials.gov

This is an active Phase 2 interventional trial registration with no posted results; it describes a planned study of a novel tau-targeting agent in early Alzheimer's disease with surrogate neuroimaging endpoints.

PreliminaryNCT07033494 Early Alzheimer's Disease Merck Sharp & Dohme

Reported

Planned enrollment340

PhasePhase 2

Primary outcome measure 1Change from Baseline in Tau PET SUVr, Basel…